Went public on 11/17/00 at $7.50 per share
Filing Range: 6.0 million shares @ $8 to $9
Shares Outstanding: 21.5 million shares
Underwriters: Lehman Brothers/Deutsche Banc Alex. Brown/ Legg Mason Wood Walker
Company Counsel: Hogan & Hartson
Manager Counsel: Latham & Watkins
Auditor: Ernst & Young LLP
Provides products and services for accelerating drug discovery. The company develops drug discovery/drug intermediates and is creating a collection of several hundred thousand novel small molecule compounds. The company performs research services to the biotechnology and pharmaceutical industries in medicinal chemistry, combinatorial chemistry, high-throughput screening and structure-based drug design. Its software is used to design sub-libraries that provide superior pharmacological properties and are biased to interact with specific biological mechanistic targets.
Mosaix Ventures LLC
HarbourVest Partners LLC.
Frazier & Co.
Boulder Ventures Ltd.
ARCH Venture Partners
Vector Fund Management LP
Mitsui & Co. Ltd.
Advent International Corp.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1998 2 Early Stage 1000.0
2 08/07/1998 5 Early Stage 6500.0
3 11/16/1999 6 Expansion 8000.1
4 08/31/2000 5 Expansion 10000.0
(Data in $ millions)
Total Revenues: 6.8
Net Income: 4.7